{"groups":[{"description":"Participants who enrolled to the study and had plasma genotyping","id":"FG000","title":"Participants With Plasma Genotyping"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"43"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"43"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Plasma Genotyping"},{"milestones":[{"achievements":[{"comment":"A total of 11 participants were found to have an activating EGFR mutation (exon 19 del or L858R).","groupId":"FG000","numSubjects":"11"}],"type":"STARTED"},{"achievements":[{"comment":"Of the 11 participants that had an activating EGFR mutation, 6 started erlotinib treatment.","groupId":"FG000","numSubjects":"6"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"}],"type":"NOT COMPLETED"}],"title":"EGFR Exon 19 Pos, Treated With Erlotinib"}]}